Urolithin A Benefits: What Studies Report

Urolithin A is not a peptide and not a plant compound that is eaten directly. It is a metabolite produced in the large intestine when gut bacteria break down ellagitannins and ellagic acid from foods such as pomegranates, walnuts and some berries. A 2022 review in Molecular Nutrition & Food Research described the metabolic pathway, the gut microbiota involved and the observation that individuals differ in which urolithins they produce, grouping people into urolithin metabotypes (PMID 35118817). That variability is one reason researchers began testing urolithin A as a directly administered compound rather than relying on dietary precursors.

This page organises the published literature by outcome domain. For each domain it states the study type, the population studied and the direction of the reported effect. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing below should be read as a claim that urolithin A produces a benefit in any individual.

How the Evidence Is Structured

The urolithin A literature falls into three tiers that are easy to confuse when outcomes are summarised together. The mechanistic tier is cell culture and worm work; the preclinical tier is rodent models of specific diseases; the human tier is a small number of randomised, placebo-controlled trials in generally healthy middle-aged and older adults. A 2024 systematic review in Ageing Research Reviews set out to collect the human trials of urolithin A relevant to ageing and reported that the human evidence base was limited in size and heterogeneous in endpoints (PMID 39002645). A 2021 review in Trends in Molecular Medicine similarly surveyed the compound across health, disease and ageing contexts and framed most disease-specific findings as preclinical (PMID 34030963).

Muscle Strength, Endurance and Physical Function

Human trials

The most-replicated human endpoints are muscular. A randomised clinical trial published in JAMA Network Open in 2022 studied older adults and reported that urolithin A supplementation over four months was associated with improved muscle endurance, measured as the number of muscle contractions to fatigue in hand and leg muscles, while the trial's primary endpoints of maximal ATP production in hand muscle and six-minute walk distance did not differ significantly from placebo (PMID 35050355). The mixed result inside a single trial is the key detail: researchers reported movement on some measures and not others.

A separate randomised trial in Cell Reports Medicine in 2022 enrolled middle-aged adults and reported improvements in muscle strength along with changes in biomarkers of mitochondrial health, while aerobic endurance and peak oxygen consumption did not change significantly over the supplementation period (PMID 35584623). Taken together, these two trials are the source of most muscle-related discussion of the compound, and both reported strength or endurance effects without corresponding changes in whole-body aerobic capacity measures (PMID 35050355, PMID 35584623).

Animal work

The original 2016 paper in Nature Medicine reported that urolithin A induced mitophagy, prolonged lifespan in C. elegans and increased muscle function in rodents — that is, in worms and animals, not humans (PMID 27400265). A 2024 review in Sports Medicine placed urolithin A among nutritional compounds studied as mitochondrial targets for maintaining muscle health and physical function during ageing, and treated the area as an active research question rather than a settled one (PMID 39060742).

Mitochondrial Biomarkers and Mitophagy

Mitophagy — the selective clearance of damaged mitochondria — is the proposed mechanism that runs through the whole literature. The first-in-human randomised, double-blind, placebo-controlled study published in Nature Metabolism in 2019 reported that oral urolithin A was bioavailable in elderly participants and that four weeks of dosing modulated plasma acylcarnitines and skeletal muscle mitochondrial gene expression, which the authors described as a molecular signature of improved mitochondrial and cellular health (PMID 32694802). These were biomarker endpoints, not clinical outcomes.

The 2022 middle-aged-adult trial also reported changes in mitochondrial health biomarkers alongside its strength findings (PMID 35584623), and the 2021 review in Trends in Molecular Medicine discussed mitophagy induction as the central mechanistic hypothesis across the compound's reported activities (PMID 34030963). Several preclinical papers used urolithin A specifically as a mitophagy-activating tool compound: a 2023 study in Redox Biology examined neutrophil extracellular traps driving intestinal microvascular endothelial ferroptosis through impaired Fundc1-dependent mitophagy (PMID 37812880), and a 2023 paper in Cell Communication and Signaling examined a mitochondrial fission–mitophagy axis in diabetes-associated cognitive dysfunction (PMID 38102662). Both are laboratory models.

Inflammation Markers

Circulating inflammatory markers appear as secondary endpoints in the human trials rather than as a primary target. The 2022 JAMA Network Open trial in older adults reported changes in plasma biomarkers alongside its muscle endurance findings (PMID 35050355), and the 2024 systematic review in Ageing Research Reviews catalogued the inflammatory and metabolic biomarker endpoints reported across the available human studies of urolithin A (PMID 39002645). A biomarker shift is not the same as a change in how a person feels or functions, and the reviews did not treat it as one (PMID 34030963).

Brain, Nerve and Eye: Preclinical Only

Searches for urolithin A and cognition or neuroprotection reach a literature that is, in the verified set here, entirely preclinical. A 2024 paper in Molecular Neurodegeneration reported that urolithin A promoted p62-dependent lysophagy and prevented acute retinal neurodegeneration in a laboratory model — an animal and cell-based finding with no human equivalent presented (PMID 38890703). The 2023 diabetes-associated cognitive dysfunction work in Cell Communication and Signaling was likewise a mechanistic animal study of a mitochondrial fission–mitophagy axis (PMID 38102662). The 2021 Trends in Molecular Medicine review grouped neurological applications among disease areas where evidence remained preclinical (PMID 34030963).

Liver and Gut: Animal Models

A 2024 study in Gut Microbes reported that urolithin A alleviated chronic alcohol-related liver disease in a mouse model, with the effect mediated by MUP1 through a gut-microbiota–liver axis (PMID 38889450). The 2023 Redox Biology work on intestinal microvascular endothelial ferroptosis sits in the same preclinical tier (PMID 37812880). Mouse liver and gut findings do not establish that the same thing happens in people, and the human trials located by the 2024 systematic review did not use liver disease endpoints (PMID 39002645).

Lifespan and "Anti-Ageing"

The lifespan claim traces to a single organism. The 2016 Nature Medicine paper reported prolonged lifespan in C. elegans, a nematode worm, together with increased muscle function in rodents (PMID 27400265). No human lifespan or mortality data exist in this literature; the 2024 systematic review that specifically examined targeting ageing with urolithin A in humans reported on functional and biomarker endpoints, not survival (PMID 39002645).

Outcome Domains at a Glance

Claimed Benefits With Little or No Supporting Evidence Here

Several outcomes commonly attached to urolithin A do not appear as endpoints in the human literature summarised by the 2024 systematic review, which focused on functional, muscular and biomarker measures in ageing-related trials (PMID 39002645). On the evidence in this verified set:

• Skin appearance, wrinkles or hair: no human trial endpoints in the studies cited here; the 2021 review framed non-muscle applications as preclinical or exploratory (PMID 34030963).
• Fat loss or body composition: not reported as an outcome in the randomised trials of muscle endurance or strength described above (PMID 35050355, PMID 35584623).
• Aerobic performance: specifically measured and specifically not significantly changed in the middle-aged trial (PMID 35584623).
• Treatment of any named disease: the liver, gut, retinal and cognitive findings were animal or cell models (PMID 38889450, PMID 38890703).

Safety and Tolerability: What Studies Report

The 2019 first-in-human study in Nature Metabolism reported a favourable safety profile with oral ingestion of urolithin A up to 1,000 mg in elderly participants over the study period (PMID 32694802). The four-month randomised trial in older adults also reported on tolerability alongside its efficacy endpoints (PMID 35050355), and the 2024 systematic review in Ageing Research Reviews summarised safety reporting across the available human studies (PMID 39002645). These were short-duration studies in selected populations; they do not describe long-term use, use during pregnancy, use alongside medications or use in people with chronic disease.

Limitations Worth Holding Onto

1. Small human base. The 2024 systematic review characterised the human trial literature on urolithin A and ageing as limited and heterogeneous (PMID 39002645).
2. Mixed within-trial results. The same trial reported improvement on secondary muscle endurance measures and no significant difference on its primary ATP and walk-distance endpoints (PMID 35050355).
3. Mechanism-first literature. Much of the body of work uses urolithin A as a mitophagy probe in cells and animals (PMID 37812880, PMID 38102662).
4. Interindividual variability. Production of urolithins from dietary precursors depends on gut microbiota composition and differs between people (PMID 35118817).
5. Populations studied. Trials enrolled middle-aged and older adults, not athletes, adolescents or clinical populations (PMID 35584623).

Read in aggregate, the published record describes a gut-derived metabolite that researchers have studied for effects on mitochondrial quality control, with human data concentrated on muscle endurance, strength and biomarker endpoints in ageing adults (PMID 39060742, PMID 39002645). Interpretation of any of this for an individual is a matter for a qualified clinician.

References

• Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents (Nature Medicine, 2016)
• The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans (Nature Metabolism, 2019)
• Impact of the Natural Compound Urolithin A on Health, Disease, and Aging (Trends in Molecular Medicine, 2021)
• Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial (JAMA Network Open, 2022)
• Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults (Cell Reports Medicine, 2022)
• Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota (Molecular Nutrition & Food Research, 2022)
• Neutrophil extracellular traps drive intestinal microvascular endothelial ferroptosis by impairing Fundc1-dependent mitophagy (Redox Biology, 2023)
• Neuron-targeted overexpression of caveolin-1 alleviates diabetes-associated cognitive dysfunction via regulating mitochondrial fission-mitophagy axis (Cell Communication and Signaling, 2023)
• Urolithin A promotes p62-dependent lysophagy to prevent acute retinal neurodegeneration (Molecular Neurodegeneration, 2024)
• MUP1 mediates urolithin A alleviation of chronic alcohol-related liver disease via gut-microbiota-liver axis (Gut Microbes, 2024)
• Targeting aging with urolithin A in humans: A systematic review (Ageing Research Reviews, 2024)
• Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function During Ageing (Sports Medicine, 2024)